ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD. Its pre-clinical products include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations for serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection treatment. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

ImmuPharma PLC

Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA

Chairman & CEO

Dr. Timothy Gary Franklin M.B.A., Ph.D.

COO & Director

Ms. Lisa  Baderoon

Head of Investor Relations & Non Executive Director

Dr. Jean-Marie  Geiger PharmD, MD

Head of Clinical Development

Dr. Laura  Mauran-Ambrosino Ph.D.

Chief Scientific Officer of ImmuPharma Biotech

Ms. Lara E. Sucheston-Campbell

Head of Clinical & Medical Affairs

Dr. Sébastien  R. Goudreau Ph.D.

CEO of ImmuPharma Biotec & Director

ImmuPharma PLC (IMM) Stock Analysis, Discussion Forum and Financial Metrics - LSE Exchange

IMM's latest dividend is 3 GBX on December 14, 2021

IMM Stock Discussion Forum and Message Board

News for LSE: IMM